Advertisement

Breast Cancer

, Volume 18, Issue 2, pp 120–123 | Cite as

Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer

  • Eriko TokunagaEmail author
  • Satoko Okada
  • Hiroyuki Kitao
  • Satoko Shiotani
  • Hiroshi Saeki
  • Kazuya Endo
  • Masaru Morita
  • Yoshihiro Kakeji
  • Yoshihiko Maehara
Original Article

Abstract

Purpose

The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified. FANCF protein is a component of the FA core complex. The methylation of CpG islands in the FANCF gene plays an important role in occurrence of ovarian cancer and also is an important regulator of cisplatin sensitivity of ovarian cancer. The purpose of this study is to investigate the frequency of FANCF methylation, and to discuss its involvement in the pathogenesis of TNBC and its potency as a predictor of cisplatin sensitivity for breast cancer.

Methods

The methylation of the FANCF gene promoter was investigated, using methylation-specific PCR, in genomic DNA of 99 invasive breast carcinoma specimens obtained from Japanese patients.

Results

FANCF methylation was recognized in only 4 of 99 cases (4.0%). No significant correlation was found between FANCF methylation and the expression of ER, PR, HER2, and TNBC.

Conclusions

FANCF methylation is a rare event in Japanese primary invasive breast cancer. This suggests it is not involved in the pathogenesis of TNBC, and it could not be used as a predictor of cisplatin sensitivity in breast cancer.

Keywords

FANCF Methylation Methylation-specific PCR Triple-negative breast cancer 

Notes

Acknowledgments

We are grateful to Ms T. Shishino and Ms K. Yamashita for their valuable technical assistance. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Conflict of interest statement

We declare that we have no conflict of interest.

References

  1. 1.
    Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846–53.PubMedCrossRefGoogle Scholar
  6. 6.
    Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Lyakhovich A, Surralles J. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett. 2006;232:99–106.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8:735–48.PubMedCrossRefGoogle Scholar
  10. 10.
    Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2:446–57.PubMedCrossRefGoogle Scholar
  11. 11.
    de Winter JP, van der Weel L, de Groot J, Stone S, Waisfisz Q, Arwert F, et al. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum Mol Genet. 2000;9:2665–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang Z, Li M, Lu S, Zhang Y, Wang H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther. 2006;5:256–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2004;23:1000–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Meyer S, White DJ, Will AM, Eden T, Sim A, Brown R, et al. No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndrome gene NBS1 by DNA hyper-methylation in sporadic childhood leukaemia. Br J Haematol. 2006;134:61–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res. 2004;64:2994–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, Hoehn H, et al. Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res. 2007;118:166–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, et al. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008;111:113–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Lim SL, Smith P, Syed N, Coens C, Wong H, van der Burg M, et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer. 2008;98:1452–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 2003;3:417–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Kimura K, Toyooka S, Tsukuda K, Yamamoto H, Suehisa H, Soh J, et al. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep. 2008;20:1265–8.PubMedGoogle Scholar
  22. 22.
    Hunter F, Xie J, Trimble C, Bur M, Li KC. Rhodamine-RCA in vivo labeling guided laser capture microdissection of cancer functional angiogenic vessels in a murine squamous cell carcinoma mouse model. Mol Cancer. 2006;5:5.PubMedCrossRefGoogle Scholar
  23. 23.
    Sun J, Chen Z, Zhu T, Yu J, Ma K, Zhang H, et al. Hypermethylated SFRP1, but none of other nine genes “informative” for western countries, is valuable for bladder cancer detection in mainland China. J Cancer Res Clin Oncol. 2009 (in press).Google Scholar
  24. 24.
    Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer. 2006;118:284–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Tokunaga E, Oki E, Nishida K, Koga T, Yoshida R, Ikeda K, et al. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. Breast Cancer Res Treat. 2006;97:199–203.PubMedCrossRefGoogle Scholar
  26. 26.
    Dhillon VS, Shahid M, Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer. 2004;3:33.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2009

Authors and Affiliations

  • Eriko Tokunaga
    • 1
    Email author
  • Satoko Okada
    • 1
  • Hiroyuki Kitao
    • 2
  • Satoko Shiotani
    • 1
  • Hiroshi Saeki
    • 1
  • Kazuya Endo
    • 1
  • Masaru Morita
    • 1
  • Yoshihiro Kakeji
    • 1
  • Yoshihiko Maehara
    • 1
    • 2
  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of Molecular Oncology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations